William Blackstock, MD
William Blackstock, Jr., MD, is a national expert in the radiotherapeutic management of cancers, with a primary focus on gastrointestinal cancer treatment. He has extensive experience collaborating with industry to lead Phase 1 and Phase 2 clinical trials investigating novel radiation treatment approaches for gastrointestinal, pancreatic, rectal and lung cancers.
About William Blackstock
William Blackstock, Jr., MD, earned a medical degree from the East Carolina University Brody School of Medicine and completed his residency and fellowship training in radiation oncology at the University of North Carolina School of Medicine at Chapel Hill. During this training, he was introduced to chemotherapeutic drug development, forming industry relationships that continue today. In 1996, after one year working as an instructor at the University of North Carolina, he joined Wake Forest School of Medicine’s Department of Radiation Oncology to focus on clinical trials research involving lung and gastrointestinal cancers. He became chair of radiation oncology in 2008.
Blackstock’s clinical expertise in gastrointestinal malignancies and pancreatic, rectal and lung cancers extends into clinical trials investigating the radiotherapeutic management of these diseases. He has been the principal investigator or co-principal investigator of numerous Phase 1 and Phase 2 chemoradiation trials examining the effects of novel drugs and treatment approaches in combination with radiation therapy, many of which are used in patient treatment today.
Over the past 15 years, Blackstock has published more than 100 journal articles and book chapters on clinical radiation oncology, radiation therapy and cancer management. He served as a member of the National Institutes of Health National Cancer Institute Board of Scientific Council and on the editorial boards for numerous journals, including the Journal of Clinical Oncology and the Journal of Gastrointestinal Oncology. He currently serves on the National Cancer Institute-designated Pancreatic Task Force and Gastrointestinal Steering Committee.
Blackstock is actively involved with leading pharmaceutical companies in clinical trials evaluating novel compounds and radiation therapy approaches for patients with pancreatic, rectal, lung and gastrointestinal cancers. He has served on the safety monitoring and advisory boards for several companies, including Glaxo SmithKline, Astra Zeneca, Sanofi-Aventis, Eli Lilly, Bristol Myers Squibb, Genentech, Novartis, Merck and General Electric.
William Blackstock, Jr., MD, chair of radiation oncology at Wake Forest School of Medicine and director of the clinical research program at Wake Forest Baptist Medical Center’s Comprehensive Cancer Center, specializes in:
- Phase 1 and 2 clinical research
- Gastrointestinal cancers
- Lung, Rectal and Pancreatic Cancers
- Radiotherapeutic management
- Drug Evaluation